Skip to main content

NovoLog Mix 50/50 Side Effects

Generic name: insulin aspart/insulin aspart protamine

Medically reviewed by Drugs.com. Last updated on Feb 22, 2024.

Note: This document contains side effect information about insulin aspart/insulin aspart protamine. Some dosage forms listed on this page may not apply to the brand name NovoLog Mix 50/50.

Applies to insulin aspart/insulin aspart protamine: subcutaneous suspension.

Serious side effects of NovoLog Mix 50/50

Along with its needed effects, insulin aspart/insulin aspart protamine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking insulin aspart/insulin aspart protamine:

More common

Incidence not known

Get emergency help immediately if any of the following symptoms of overdose occur while taking insulin aspart/insulin aspart protamine:

Symptoms of overdose

Other side effects of NovoLog Mix 50/50

Some side effects of insulin aspart/insulin aspart protamine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Most common

For Healthcare Professionals

Applies to insulin aspart/insulin aspart protamine: subcutaneous suspension.

General

The most common adverse reactions observed with insulin therapy include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus.[Ref]

Metabolic

Hypoglycemia is the most frequently reported adverse reaction with insulin therapy. It occurs if the dose of the insulin is too high in relation to the insulin requirement. In clinical trials, the frequency of hypoglycemia varied with patient population, dose regimens, and level of glycemic control. Weight gain has been attributed to the anabolic effects of insulin and the decrease in glycosuria.[Ref]

Very common (10% or more): Hypoglycemia (69%)

Frequency not reported: Weight gain[Ref]

Hypersensitivity

Very rare (less than 0.01%): Anaphylactic reactions

Frequency not reported: Allergic reactions[Ref]

Local

Injection site reactions including pain, redness, hives, inflammation, bruising, swelling, and itching, may occur. These reactions are usually transitory.[Ref]

Frequency not reported: Injection site reactions[Ref]

Ocular

Frequency not reported: Transient, reversible ophthalmologic refraction disorder, worsening of diabetic retinopathy[Ref]

Rapid improvement or intensification of in glucose control has been associated with transitory, reversible ophthalmologic refraction disorder; however, long-term glycemic control decreases the risk of diabetic retinopathy.[Ref]

Cardiovascular

Frequency not reported: Peripheral edema[Ref]

Insulin may cause sodium retention and edema, especially if previously poor metabolic control is improved by intensified insulin therapy.[Ref]

Dermatologic

Frequency not reported: Lipodystrophy, rash, pruritus[Ref]

Gastrointestinal

Common (1% to 10%): Dyspepsia, diarrhea, abdominal pain[Ref]

Immunologic

Common (1% to 10%): Influenza-like symptoms

Frequency not reported: Anti-insulin antibodies[Ref]

In a 3-month, open-label study, anti-insulin antibodies and cross-reacting anti-insulin antibodies were monitored in patients using this insulin compared with an insulin mix of 70% NPH (human insulin isophane suspension) and 30% regular (human insulin injection). Changes in cross-reactive antibodies were more common after this mix but these changes did not correlate with a change in HbA1c or increase in insulin dose. The clinical significance of these antibodies has not been established. Antibodies did not increase further after long-term exposure (greater than 6 months).[Ref]

Musculoskeletal

Common (1% to 10%): Back pain, skeletal pain[Ref]

Nervous system

Rapid improvement or intensification of in glucose control has been associated with acute and painful peripheral neuropathy; however, long-term glycemic control decreases the risk of neuropathy.[Ref]

Very common (10% or more): Headache (19%)

Common (1% to 10%): Neuropathy[Ref]

Other

Postmarketing reports: Medication errors in which other insulins have been accidentally substituted[Ref]

Respiratory

Common (1% to 10%): Pharyngitis, rhinitis , upper respiratory tract infection[Ref]

More about NovoLog Mix 50/50 (insulin aspart/insulin aspart protamine)

Other formulations

Related treatment guides

References

1. Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine). Novo Nordisk Pharmaceuticals Inc. 2022.

2. Product Information. NovoLOG Mix 70/30 FlexPen (insulin aspart-insulin aspart protamine). Novo Nordisk Pharmaceuticals Inc. 2022.

3. Cerner Multum, Inc. UK Summary of Product Characteristics.

4. Cerner Multum, Inc. Australian Product Information.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.